Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(22 sites)
China
Second Hospital of Army Military Medical University, Chongqing, Chongqing Municipality Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian People's Hospital of Guangdong Province, Guangzhou, Guangdong Shenzhen Hospital of Peking University, Shenzhen, Guangdong Shunde Hospital of Southern Medical University, Shunde, Guangdong Wuhan First Hospital, Wuhan, Hubei Jiangsu Province Hospital of Integrated Chinese and Western Medicine, Nanjing, Jiangsu Xuzhou Medical University Hospital, Xuzhou, Jiangsu The Second Hospital of Dalian Medical University, Dalian, Liaoning The First Hospital of China Medical University, Shenyang, Liaoning Hospital of Liaoning University of Chinese Medicine, Shenyang, Liaoning People's Hospital of Liaoning Province, Shenyang, Liaoning The First Hospital of Qingdao University, Qingdao, Shandong Weifang People's Hospital, Weifang, Shandong Weihai Hospital, Weihai, Shandong Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality Shanghai 10th People's Hospital, Shanghai, Shanghai Municipality Shanghai First People's Hospital, Shanghai, Shanghai Municipality Shanghai Pudong Zhoupu Hospital, Shanghai, Shanghai Municipality First People's Hospital of Yunnan Province, Kunming, Yunnan The First Hospital of Kunming Medical University, Kunming, Yunnan Zhejiang Province Hospital of Integrated Chinese and Western Medicine, Hangzhou, Zhejiang